In a study of mutational status of TP53, NPM1, MLL/PTD and FLT3 in 235 patients, including 214 with de novo AML, 13 therapy-related AML and 8 AML evolving from myelodysplastic syndrome, 1 of the 33 TP53-mutated patients had concurrent MLL/PTD and another 1 patient had FLT3 length mutation.8NPM1 mutation was not observed in patients with TP53 mutation. This evidence concerns the gene KMT2A and myelodysplastic syndrome.